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 Summary
 Background: To evaluate the radiological and clinical therapeutic effectiveness of 90Y-octreotate [DOTATATE] in 
patients with progressive somatostatin receptor–positive midgut neuroendocrine carcinomas (GEP-
NETs).
 Material/Methods: The study group: 34 patients, with histological proven extensive non-resectable and progressive 
midgut GEP-NETs. Radionuclide therapy (90Y-DOTATATE) was given i.v. with a mean activity per 
administration 3,82 GBq. Initial clinical tumor responses were assessed 6–7 weeks after therapy 
completion and then once 3-monthly. The objective tumor response was classified according to the 
RECIST, initially between 4-6 months and then after each of the 6 months interval.
 Results: At 6 months after treatment completion, radiological tumor response was observed in 6 subjects 
with PR (19%), 25 presented SD (78%) and single had PD (3%). Overall clinical response to therapy at 
6 months follow-up was observed in 23 patients (68%), SD in 5 patients (15%) and PD in 6 (18%). A 
year after therapy radiological tumour response was seen in 11 patients (44%), SD had 12 subjects 
(44%) and DP was noted in 2 patients. Two years after completed therapy PR was seen in 6 patients 
(33%), SD in additional 11 subjects (61%), single patient had PD. Clinical response to treatment in 
terms of PR and SD were noted in 22 patients (88%) after 1 year and in 14 patients (87%) after 2 
years. Median PFS was 20 months, while the median OS was 23 months. In the 6 patients with 
clinical PD within initial 6 months the median PFS was 6 months and OS 11 months, while in those 
with SD or PR PFS was 22 months and OS 26 months (P<0.05).
 Conclusions: Therapy with 90Y-DOTATATE is effective in terms of clinical response, however the radiological 
response measured by the RECIST criteria underestimates benefits of this type of therapy in 
patients with progressive somatostatin receptor–positive midgut neuroendocrine carcinomas.
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Background
Current therapeutic options for patients with progressive 
metastatic neuroendocrine carcinoma of gastroenteropan-
creatic origin (GEP-NETs) are limited. In those patients with 
midgut GEP-NET chemotherapy is not only toxic but also 
ineffective [1]. When a metastatic midgut neuroendocrine 
carcinoma is responsible for hormonal overproduction (i.e. 
carcinoid syndrome), treatment with conventional soma-
tostatin analogues is method of choice in most of the cases, 
due to symptoms relief. However, the size of the tumor is 
reduced in very rare cases [2–4].
These limited approaches using standard oncological treat-
ments in patients with progressive metastatic GEP-NETs 
have led towards the development of radionuclide tumor-
targeting strategies [5–7]. The peptide radionuclide target 
therapy consists in the elimination of cancer cells using high 
energetic b-electrons, with lower toxicity to other normal tis-
sues, due to direct binding [5,6,8]. The recommendation of the 
European Neuroendocrine Tumor Society (ENETS) is that tar-
geted radionuclide treatment using somatostatin analogues 
should be considered in patients with midgut GEP-NET [9].
The previous data from used 90Y [DOTATOC] indicates that 
this radionuclide treatment produces radiological partial 
response (PR) in a 10–35% patients [5,6].
Classical response evaluation in solid tumours (RECIST 
or WHO) uses radiological imaging approaches to mea-
sure changes of the tumour size before and after therapy. 
In these terms imaging requires a well-defined structural 
lesion which can be assessed and compared, if there is a 
reduction of tumour size during treatment as the basis for 
presumed clinical benefit [10]. However, with the devel-
opment of new therapeutic strategies using for example 
peptide receptor radiotherapy (PRRT) classical structural 
radiological imaging could be inappropriate as neuroendo-
crine tumours would not significantly reduce in size after 
therapy as previous reports indicated [5,6,11–14].
This study represents clinical trial to report the efficacy 90Y 
DOTATATE therapy after at least 6 months of follow-up period .
The Aim of this study
The aim of this study was to determine the radiological and 
clinical efficacy 90Y DOTATATE therapy of disseminated 
midgut GEP-NET carcinomas eligible or appropriate for 
other forms of therapy.
Material and Methods
This was a prospective single site open-label study, approved 
by the Clinical Ethics Committee of the Central Clinical 
Hospital Ministry of Internal Affairs & Administration, 
where study was performed. Prior to the study's inclusion, 
written consent was obtained from all patients.
Patients
The study group comprised of 34 patients including 20 
females, mean age 57 years (range 40–73 years). The inclu-
sion criteria were as follows: histological diagnosis of mid-
gut neuroendocrine carcinomas, WHO group 2 [9] with 
metastatic disease and evidence of clinical, biochemical 
(chromogranin A – CgA, 5HIAA) and/or imaging progres-
sion (CT or somatostatin receptor scintigraphy – SRS, with 
an increase of the size of tumor and/or increased number 
of lesions). This was assessed for a minimum period of 6 
months prior to treatment.
Somatostatin receptor scintigraphy (SRS)
All patients were imaged with 99mTc-[HYNIC, Tyr3]octreotide 
[HYNICTOC] with radiotracer avid lesions within the liver 
or any other part of the body having uptake at least or 
greater than normal liver, most within the abdomen and 
pelvis. The preparation of 99mTc-HYNICTOC before admin-
istration was described elsewhere [15,16]. Anterior and pos-
terior whole body images, abdominal SPECT, including liver 
and any additionally required SPECT images were obtained 
3–4 h after injection of 480–560 MBq of 99mTc-HYNICTOC.
Study parameters
None of the patients received prior treatment with other 
radiolabelled somatostatin analogues. In those patients 
receiving long acting somatostatin analogues i.m, the drugs 
were discontinued at least 4 weeks before radionuclide treat-
ment, and re-introduced 3 to 4 days after therapy. Exclusion 
criteria were as follows: Hb <8 g/dl, WBC <2×103/ml, 
platelets <80×103/ml, creatinine level >1.2 mg/dL or GFR 
<30ml/min, and poor performance status (WHO – Zubrod 
status 3 and 4). Contraindications to treatment included: 
pregnancy, myelosuppression, and renal failure.
Preparation of radiotracer
Labeling
100 μg [DOTATATE] (DOTA-D-Phe1-Tyr3-octreotate) (piChem, 
Graz, Austria) with 50.0 mg ascorbic acid and 6.0 mg 5-
dihydroxybenzoic acid were freeze-dried to form the kit. 
The kits were checked for sterility and bacterial endotox-
ines prior to use. The content of the kit was dissolved in not 
more than 0.5 ml 90Y chloride (non carrier-added) in 0.05 M 
HCl (POLATOM, Poland) with the desired activity for treat-
ment (max. activity per kit – 7.5 GBq 90Y) and filled up to 1 
ml with saline. The mixture was then incubated at 95°C for 
25 min. After cooling down to room temperature the vol-
ume was adjusted to 2 ml with saline. Immediately before 
therapy the mixture was dissolved saline to final 50 ml.
Radiochemical purity (RCP) control
90Y-DOTATATE was checked for RCP by analytical HPLC 
and SepPak C18. All radiolabelled peptides showed a radio-
chemical purity of >99.0%, with no need for purification. 
The specific activities of radiolabelled peptide varied in the 
range 44.9–107.1 MBq/nmol (average 73.5±10.2 MBq/nmol).
Therapy – administration protocol
Ondansetron (GSK, UK) 8 mg was administered orally 
30 min, before the start of i.v. infusion of amino acids 
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(Vamin 18, Fresenius-Kabi, Germany) 1500 ml, initiated 
by means of a slow i.v. injection, approximately 1.5–2 h 
before radiopharmaceutical administration. 90Y-DOTATATE 
was administered via an injection pump system together 
with the amino acid infusion. The mean treatment activ-
ity 3.82 GBq was injected up to 20 min. The mean interval 
between therapies was 7 weeks (range 6–9 weeks). Patients 
were treated up to a cumulative activity of 11.2 GBq. Due 
to pure beta emission of 90Y internal dosimetry was evalu-
ated, based on previous reports considering 90Y-DOTATOC 
treatment, which were performed using MIRD formalism. 
Using the cumulative dose mentioned above we expected 
similar radiation doses (bone marrow less then 2 Gy, and 
the radiation dose to the kidneys below 23 Gy) [17,18].
Biodistribution of the radiotracer
Before treatment each patient underwent standard soma-
tostatin receptor scintigraphy (SRS) using 99mTc-HYNICTOC 
to show the uptake of the isotope. In the majority of disease 
sites the radioisotope activity was expected to be greater 
than physiological liver activity (Krenning score at least 2). 
In order to confirm that the therapeutic dose had a similar 
biodistribution, “Bremsstrahlung” images were acquired at 
12-20 hours after the administration of 90Y-DOTATATE using 
a dual head gamma camera (e-cam; Siemens) equipped with 
high energy collimation with a photopeak centered on 95 
keV with a 50% window.
Safety and therapeutic effect
Patients were assessed clinically for general health and any 
tumor specific symptoms were recorded before treatment, 
6 weeks after treatment and then at 3–6 monthly intervals. 
Routine hematology, liver and kidney function tests were 
measured before and then 10, and 20 days after each ther-
apy session. Hormone levels in case of secretory tumors 
and chromogranin A (CgA) were measured before the start 
of therapy, 6 weeks after completion of the last cycle of 
therapy followed at 3 monthly intervals thereafter. A WHO 
Performance Status was estimated in each case before the 
beginning of therapy and 6 weeks after the completion of 
therapy. Improvement of clinical symptoms was assessed 
as clinical benefits, but not as an objective response.
Assessment of Effectiveness
The radiological response to therapy (RECIST)
Tumors on CT scans were measured and scored, according 
to the RECIST [4]. All patients were subjected to a three 
phase contrast enhanced spiral multidetector CT (Aquilion 
16, Toshiba), and 1 mm slices within the 2 months prior 
to the first therapy. Post-therapeutic imaging was per-
formed after 4–6 months of follow-up. The CT images were 
interpreted and measured using a dedicated workstation 
(Vitrea™, Toshiba), with total freedom for window and level 
adjustments, and for the magnification of each image at 
the time of analysis. Every tumor was measured in single 
maximal dimensions in the transverse plane and its larg-
est perpendicular diameter on the same image. Pre and post 
therapy CT images were compare to each other together to 
make diagnosis of potential changes more certain
Biological tumor response
The biological tumor response was determined by means 
of serial measurements of plasma chromogranin-A (CgA), 
24-hour urinary 5-hydroxyindole acetic acid (5-HIAA). 
Results were obtained at pre-treatment, 6-8 weeks post 
therapy and then at 3 monthly intervals.
Clinical response and performance status
The patients were assessed for clinical responses by com-
pleting a self-assessment questionnaire, and during physi-
cian directed interviews conducted before the beginning 
of treatment and 4–6 weeks following each treatment 
cycle. The items they assessed included appetite, malaise, 
weight loss, and the presence and intensity and frequency 
of abdominal pain, diarrhea, flushing, nausea, vomiting, 
fever, wheezing, and abdominal bloating. Any analge-
sic and somatostatin analogue requirements before and 
after treatment were recorded. The patients' clinical stage 
was assessed before and 6 weeks after completed therapy 
using standard WHO status.
Statistical analysis
Overall survival (OS) and progression free survival (PFS) 
were evaluated using Kaplan-Meier's method. Comparison 
of OS and PFS between different groups of patients were 
assessed using the Cox-Mantel test. Differences in WHO 
status in patients before therapy and after completed radio-
nuclide therapy were performed using Wilcoxon's Matched 
Pairs Test. P<0.05 was considered as statistically signifi-
cant.
Results
Of the 34 patients treated, 5 had as initial diagnosis small 
midgut tumour base on recent WHO classification of 
GEP-NET pathology, as pT2, 10 had pT3 and 19 had ini-
tial pT4 tumour [19]. Summarized clinical data of treated 
patients are presented on [Table 1], including initial WHO 
performing status, pathological and clinical initial tumor 
staging, previous systemic therapy, for all subjects and 
those with secretor and non-secretor tumour.
A total of 100 therapies were performed with mean admin-
istered activity of 11,2 GBq (range 4.1–16.2 GBq) per patient 
(mean 3.82 GBq per therapy), most of them 24 subjects had 
3 times and 4 patients had 4 and next 6 two therapy ses-
sions. The biodistribution of the 90Y-DOTATATE was seen 
in the “Bremsstrahlung” images and in most cases perfectly 
matched the diagnostic 99mTc-HYNICTOC image performed 
before therapy.
Toxicity
No major sudden acute adverse events were recorded 
either during the therapy session or within 24 h of 90Y-
DOTATATE therapy. Mild nausea and vomiting, (probably 
due to the co-administration of amino acid infusion) were 
the only adverse events. Those effects disappear sponta-
neously within 6 h, after discontinuation of the AA infu-
sion.
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Therapeutic effect
Radiological (RECIST) tumor response data was available 
in 32 patients who completed at least two or more cycles 
of therapy. In the remaining 2 cases patient died after their 
second cycle of treatment before a radiological response 
could be assessed. On CT imaging performed 4–6 months 
after the last cycle therapy 6 cases (19%) had a substantial 
reduction of tumor size, as partial response (PR), 25 patients 
(78%) were defined as disease stability (SD). A one year after 
the completion of treatment, radiological tumor response 
was evaluated in 25 patients. In 11 subjects (44%) had PR 
(Figure 1A–C), 2 patients (8%) had disease progression, due 
to continuous tumor growth, others 12 patients had SD 
(48%). A two years after PRRT radiological tumor response 
was evaluated in 18 patients, 6 of them still had PR (33%), 
11 subjects had SD (61%) and single had PD (6%). Details of 
radiological tumor response including all subjects and those 
with secretor and non secretor cancers is presented on 
(Table 2). Graphical presentation changes of max LD base on 
RECIST in all patients after 6, 12 and 24 months of clinical 
follow-up is shown as waterfall charts on (Figure 2A–C).
Clinical response
Carcinoid syndrome with dominant diarrhoea (bowel move-
ments more than three times a day) was reported in 19 
patients before therapy in more than half of the cases (53%) 
cases there was reduction of diarrhoea, and additional in 
4 cases bowel movements back to normal. Minor relief in 
the frequency of bowel motility was noticed in 9 patients. 
Second characteristic sign of the carcinoid syndrome a 
flushing was reported in 15 subjects pre-therapy with sig-
nificant reduction after therapy in 9 of them. Abdominal 
pain was reported in 16 patients before 90Y-DOTATATE ther-
apy, 12 of them noted a reduction of pain, a during therapy 
and most of them 4-8 weeks after therapy, with a reduction 
in analgesic and other medication administration.
Before therapy WHO status 1 noted in 22 cases (65%) WHO 
status 2 noted in 12 cases (35%). After therapy WHO status 
0 noted in 3 cases (10%), WHO status 1 in 26 cases (80%) 
and WHO 2 in 4 cases (P<0.05). Details of clinical response 
presented on (Table 2).
PFS and OS
In this population of patients median PFS was 20 months 
(±95%CI 16–22.4); median OS was 23 months (±95%CI 
19.1–26.6) (Figure 3). In those 6 patients with early dis-
ease progression the median PFS was 6 months, and OS 11 
months. There was no significant differences of PFS and OS 
between group of patients with secretor and non-secretor 
midgut cancers (P>0.05). Survival rate at 2 years was 78% 
for all patients and 80% in those with non-secretor midgut 
cancer and 75% in those with secretor midgut tumours.
Characteristics
All Non-Secretor Secretor
No percent No percent No percent
No of patients 34 100 13 38 21 62
Age
 Mean age 57 54.8 58.3
 Range 40–73 40–69 48–73
Sex
 Female 20 53 9 69 11 52
 Male 14 47 4 31 10 48
Initial Performance Status
 WHO status=1 22 65 12 92 10 48
 WHO status=2 12 35 1 8 11 52
 Presence of Primary Tumour 14 41 4 31 10 48
 Previous Chemotherapy 21 62 10 77 11 52
 Previous Analogues SSTR 15 44 4 13 10 48
 Liver Involvement 28 82 10 77 18 86
 Other Sides of Mts 8 24 3 23 5 38
SRS (Krenning uptake score)
 4 23 68 8 62 15 62
 3 11 32 5 38 6 38
Table 1.  Patients characteristics, including clinical data, type of therapy and secretory and non secretory cancers (n=34 subjects with midgut 
GEP-NET, WHO group 2).
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Discussion
Patients with midgut neuroendocrine cancers often present 
with advanced disease, with non-resectable tumor depos-
its and complete cure of these patients is limited. In these 
cases only palliation can be offered [1,9].
The use of radionuclide target (labelled somatostatin ana-
logues) therapy to deliver a high energetic b emitter into 
tumor tissues has been developed over the past 8 years 
[17–18]. Current European Neuroendocrine Tumor Society 
(ENETS) recommendations indicated use of radiolabelled 
somatostatin analogues in patients with midgut GEP-NET 
(WHO group 2).
This type of therapy with targeted mechanisms of action, 
have demonstrated significant limitation and unsuitabil-
ity in terms of structural tumor evaluation that measure 
only size of the lesions like standard RECIST or WHO 
classification do. Single or bi-dimensional evaluation of 
tumour size reduction after therapy currently changes 
the paradigm of tumour response. Our results show the 
discrepancy between radiological and clinical response 
on 90Y-DOTATATE therapy. This refers to PR estimated by 
radiological and clinical criteria, which is especially seen 
after 6 months after therapy completion: 19% vs 68%. This 
was less evident during the follow-up period: 44% vs 64% 
at 12 months and 33% vs 39% at 24 months. These results 
are similar to those presented in others reports, consider 
first 6 months of follow-up, which indicated relatively 
low rate of radiological responses of 22–34% during first 6 
months of follow-up [5,6,17,18].
In fact significant number of patients had disease stabili-
zation as radiological response, which could be correlated 
as some kind of benefits in group of patients with exten-
sive progressive cancer. Stable disease in our study seems 
to be higher then others reports, which indicated an objec-
tive response about 60–65% rate. The explanation of these 
results could be attributed to the different peptide used by 
others described in majority reports [5,6,17,18,20]. In our 
study [DOTATATE] analogues was used, with higher affin-
ity towards SST2 receptors, which have potentially better 
efficacy during therapy. There are few reports using this 
peptide labelled with 177Lu, 90Y, or mix of both radioiso-
topes [11,13,21,22] in patients with advanced GEP-NET. 
Radiological disease stability was seen in 76% and PR was 
seen in 17% of cases, these results perfectly mach in our 
rate with SD 78% and PR 19%.
Objective radiological response evaluation is important to 
assess the treatment efficacy of any anticancer drugs. Some 
kind of standardisations of imaging results is very impor-
tant to compare different type of therapy, or different anti-
cancer drugs, because clinical evaluation could be subjec-
tive. It is generally accepted that a decrease in tumor size 
correlated with treatment effect [23,24].
As mentioned before, in terms of objective response to ther-
apy using RECIST or WHO criteria there is some criticism, 
due to non-adequate discrimination of the real benefits 
of therapy. Common sense would be to use other criteria, 
such as time to progression or overall survival, consider-
ing treatment efficacy [24]. The common clinical prob-
lem in extensive neuroendocrine carcinomas is connected 
Figure 1.  A 58 years old male with clinically carcinoid syndrome, 
histology – NECLM (midgut carcinoid, WHO group 2). 
(A) Standard CT scan after i.v. contrast enhancement (portal-
venous phase), before 90Y DOTATATE treatment; (B) CT scan, 
6 months after completed radionuclide therapy, RECIST – PR. 
Clinically almost no symptoms of carcinoid syndrome; (C) 12 
months after completed therapy, RECIST – PR.
C
B
A
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A Figure 2.  Changes of tumour and/or metastasis 
lesions size (max LD base on RECIST) in 
all patients with midgut GEP-NET treated 
90Y-DOATATE during clinical follow-up. 
A. After 6 months (N=32), B. After 12 
months (N=25) and C after 24 months 
(N=18).
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Time of follow-up 
RECIST
Time of follow-up
Clinical
No Percent No Percent
6 Months (N=32) 6 Months (N=34)
PR 6 19 PR 23 68
SD 25 78 SD 5 14
PD 1 3 PD 6 18
12 Months (N=25) 12 Months (N=25)
PR 11 44 PR 16 64
SD 12 48 SD 6 24
PD 2 8 PD 3 12
24 Months (N=18) 24 Months (N=18)
PR 6 33 PR 7 39
SD 11 61 SD 9 50
PD 1 6 PD 2 11
Table 2. Comparison of radiological response (RECIST) and clinical response in group of 34 patients with midgut GEP-NET.
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with therapeutic benefit although without tumor regres-
sion, observed after target radionuclide therapy. Additional 
it seems to be that complete or partial responses using 
RECIST or WHO cannot be the adequate end points of any 
current targeted clinical trials. In some cases, overall sur-
vival, progression-free survival or disease control could be 
more adequate end point of the study than RECIST or WHO 
criteria of target therapy efficacy. OS and PFS in our group 
of patients during clinical follow-up had similar rate as pre-
sented by others long terms efficacy those by Kwekkeboom 
et al. [13], and Baum et al. [22]. The number of patients in 
this study was relatively small, which is some kind of limi-
tation. Except for 2 studies mentioned above [13,22] which 
enrolled over 300 patients, most presented data comprising 
less than 100 patients [5,6,11,20]. However, neuroendocrine 
tumours are relatively rare, there is no possibility to match 
with a control group for statistical comparison or random-
ized the study. In our study we tried to compare patients 
with secretory and non-secretory carcinomas, with no sig-
nificant difference between groups, considering OS or PFS, 
which indicated that secretory and non-secretory cancer 
patients presented a similar natural history.
Using RECIST or WHO response criteria we are aware 
other limitation of structural measurement alone in poten-
tial tumour reduction after therapy [23]. It could be relat-
ed to often ill-defined and confluent metastatic lesions, 
which could provide different tumour margins definition. 
Additional if there is multiple metastatic deposits the selec-
tion of target lesions and again measurements of them after 
therapy, could be source of differences in real response 
[23,25]. To avoid these limitation in our study all images 
and evaluation of tumour response was done by single radi-
ologist (A.S), who read images before and after therapy the 
same time. More precisely will be measurement all cancer 
deposits, due to differences in treatment response in dif-
ferent lesions, but it will be impractical and in some cases 
impossible.
The future of tumour response evaluation, using structural 
imaging, could be made to measure tumor volume, base on 
widespread multidetector CT, or MR imaging, and post-
image processing procedures to evaluation of the real lon-
gest diameter of a lesion [26].
Conclusions
•  Intravenous therapy using 90Y-DOTATATE is effective pal-
liative treatment method for patients with progressive 
extensive somatostatin receptor–positive midgut GEP-
NET.
•  The objective radiological response and clinical response, 
is comparable with previous data considering.
•  Further investigations using structural and functional 
imaging approaches should be used to more precisely 
assess tumour response on 90Y-DOTATATE therapy, par-
ticular within first 6 months after therapy.
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treated 90Y-DOTATATE.
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